Organisation paid for research Program year 2025 Source: CMS Open Payments

First Surgical Hospital

Neither a doctor nor a teaching hospital

Research payments

$16,439,501

27 payments

Through program year 2025, First Surgical Hospital is reported as receiving $16,439,501 in research payments, across 27 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $2,623,638 3
2024 Research $943,187 5
2023 Research $11,073,638 5
2022 Research $1,297,466 3
2021 Research $468,154 5
2020 Research $8,355 4
2019 Research $25,064 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. Vertex Pharmaceuticals Incorporated $16,401,070 18 payments
  2. Pacira Pharmaceuticals Incorporated $38,431 9 payments
Studies the money was for Research payments · program years 2019–2025
  1. Evaluation of Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty $7,316,407 2 payments
  2. A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy $4,251,119 3 payments
  3. A Phase 2, Randomized, Double-blind, Placebo controlled, Dose-ranging Study Evaluating the Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy $1,285,101 2 payments
  4. A Phase 3b, Open-label, Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine As Part of Multimodal Therapy for Acute Pain After Aesthetic or Reconstructive Surgeries $1,238,236 1 payment
  5. A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy $1,015,488 3 payments
  6. A Phase 2 Randomized Double - blind Placebo - controlled Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty $467,468 1 payment
  7. A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain $453,034 2 payments
  8. A Phase 2 randomized double blind placebo controlled study evaluating the efficacy and safety of VX-548 for acute pain after an abdominoplasty $264,019 1 payment
  9. A Phase 3b, Open-label, Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine As Part of Multimodal Therapy for Acute Pain After Laparoscopic Procedures of the Intraperitoneal or Retroperitoneal Cavities or Arthroscopic Orthopedic Procedures $109,323 2 payments
  10. A Phase 1, Pilot, Open Label, Dose Escalation Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety, of Exparel Administered As Sciatic Nerve Block in Popliteal Fossa, for Postsurgical Analgesia in Subjects Undergoing Bunionectomy $13,367 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record